文章核心观点 公司宣布出售业务的最终购买价格，交易完成并在2025年第一季度录得利润 [2][3] 交易情况 - 2024年11月20日公司签署协议将项目人员和挪威咨询业务出售给瑞典公司NYAB AB [2] - 交易需股东大会批准，2024年12月16日召开特别股东大会批准该交易，2025年1月2日完成交易 [2] 购买价格与利润 - 2025年1月2日交易时宣布的初步购买价格为3530万欧元，最终购买价格为3640万欧元 [3] - 2025年第一季度因终止经营业务录得700万欧元利润，交易相关成本已从该净额中扣除 [3] 公司业务与规模 - 公司通过子公司在北欧国家提供可再生能源项目开发和建设服务，旗下Proha Oy提供项目管理软件及相关服务，eSite提供工业虚拟现实服务 [3] - 2024年集团净销售额为9930万欧元，员工约200人 [3]

Q1 2025 Sales Press release - Paris, April 29th, 2025 Continued growth in Q1 2025, driven by performance in France, EMEA, and wholesale partners Q1 2025 sales at €297m, increasing by 2.6% on an organic0F0F1 basis vs. Q1 2024 at €287m Sales growth driven by France (+4%) and EMEA (+9%); Positive trend in America (+2%) despite high comparable; Asia still impacted by China network optimizationGroup is back to like-for-like growth (+1.8%) Stabilized like-for-like performance in Asia, indicating that the action p ...

Utrecht, 29 April 2025 Aalberts today reports that it has repurchased 105,706 of its own shares in the period from 22 April 2025, up to and including 25 April 2025, for an amount of EUR 2,828,071.84, so at an average share price of EUR 26.75. This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be cancel ...

The retail turnover (including VAT) of Apranga Group reached EUR 73.8 million in Q1 2025 and was by 2.2% higher than in corresponding period of 2024. The unaudited consolidated profit before income tax of Apranga Group amounted to EUR 0.4 million in 3 months 2025, while Apranga Group had the profit of EUR 1.3 million in the same period of 2024. EBITDA of Apranga Group reached EUR 5.9 million in 3 months 2025, while it amounted to EUR 6.4 million in corresponding period of 2024. The unaudited interim consoli ...

The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level of diagnostic precision not possible with traditional manual scoring methods. This Breakthrough Device Designation (BDD) demonstrates Roche’s continued innovation in companion diagnostics and digital pathology to enable more precise diagnosis in oncology. Basel, 29 April 2025 - Roc ...

Transformational year following the successful launch of AGAMREE® Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces its full year results for the year ended 31 December 2024. Dario Eklund, CEO of Santhera said: “The year 2024 marked a transformational period for Santhera, with the successful launch of AGAMREE® for the treatment of Duchenne muscular dystrophy in Germany and Austria, and in the U.S. by our licensing partner Catalyst Pharmaceuticals. Santhera ended th ...

Today, BAWAG Group released its results for the first quarter 2025, reporting a net profit of € 201 million, earnings per share of € 2.54, and a RoTCE of 25.8%. Pre-provision profits were at € 336 million and the cost-income ratio at 37%. The first quarter 2025 represents the starting point as a larger group. After the closing of our most recent acquisition, Barclays Consumer Bank Europe, on February 1, 2025, the first quarter results include a full quarter of Knab and two months of Barclays Consumer Bank E ...

The report is available as an online version and as a PDF. Highlights Robust sales performance, with revenue increasing by 100 percent compared to last year.Strong gross margin of 56.6 percent, significantly higher than in the segments we are exiting.Monetized our iris recognition technology through a licensing agreement with Smart Eye.As part of our strategic exit from Mobile and PC, the associated results are classified as discontinued operations, to provide a more transparent view of our ongoing business ...

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto (+22% cc), Kisqali (+56% cc), Kesimpta (+43% cc), Cosentyx (+18% cc), Leqvio (+72% cc) and Scemblix (+76% cc) Core operating income margin1 reached 42.1%, +400 basis points (cc), mainly driven by higher net sales Operating income grew +44% (cc, +38% USD); net income up +37% (cc, +34% USD)Core EPS1 grew +31% (cc, ...

Hydro’s adjusted EBITDA for the first quarter of 2025 was NOK 9,516 million, up from NOK 5,411 million in the same quarter last year. The results increased from higher alumina and all-in aluminium prices, and positive currency effects. This was partly offset by higher raw material costs, lower Extrusions volumes and margins, lower alumina sales volumes, and higher fixed cost resulting in an adjusted RoaCE of 10.7 percent over the last twelve months and a free cash flow of NOK 1.3 billion. Strong upstream re ...